Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБОУ ВПО Нижегородская государственная медицинская академия Минздрава РФ
Список исп. литературыСкрыть список 1. Тиганов A.C., Снежневский А.В., Орловская Д.Д. и др. Руководство по психиатрии. В 2 т. Т. 1. Под ред. А.С.Тиганова. М.: Медицина, 1999; с. 514–5. 2. Sunden SL, Renduchintala MS, Park EI et al. Betaine-homocysteine methyltransferase expression in porcine and human tissues and chromosomal localization of the human gene. Arch Biochem Biophys 1997; 345 (1): 171–4. 3. Muntjewerff JW, Blom HJ. Aberrant folate status in schizophrenic patients: what is the evidence? Prog Neuropsychopharmacol Biol Psychiat 2005; 29 (7): 1133–9. 4. Zintzaras E. C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies. Psychiat Gen 2006; 16 (3): 105–15. 5. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiat 2006; 11 (2): 143–9. 6. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epid 2007; 165: 1–13. 7. Regland B, Germgård T, Gottfries CG et al. Homozygous thermolabile methylenetetrahydrofolate reductase in schizophrenia-like psychosis. J Neural Transm 1997; 104 (8–9): 931–41. 8. Tan EC, Chong SA, Lim LC et al. Genetic analysis of the thermolabile methylenetetrahydrofolate reductase variant in schizophrenia and mood disorders. Psychiat Gen 2004; 14 (4): 227–31. 9. Arinami T, Yamada N, Yamakawa-Kobayashi K et al. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Gen 1997; 74 (5): 526–8. 10. Sazci A, Ergül E, Güzelhan Y et al. Methylenetetrahydrofolate reductase gene polymorphisms in patients with schizophrenia. Brain Res Mol Brain Res 2003; 117 (1): 104–7. 11. Vares M, Saetre P, Deng H et al. Association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and age of onset in schizophrenia. Am J Med Gen B Neuropsychiat Gen 2009. 12. Muntjewerff J, Kahn R, Blom H, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis secular. Psychiat 2006; 11: 143–9. 13. Peerbooms OL, van Os J, Drukker M et al. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? Brain Behav Immun 2011; 25 (8): 1530–43. 14. Allen NC, Bagade S, McQueen MB et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature 2008; 40: 827–34. 15. Maarten van den buuse modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 2010; 36 (2): 246–70. 16. Roffman JL, Brohawn DG, Nitenson AZ et al. Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr Bull 2011. 17. Regland B, Johansson BV, Grenfeldt B et al. Homocysteinemia is a common feature of schizophrenia. J Neural Transm Gen Sect 1995; 100 (2): 165–9. 18. Mabrouk H, Douki W, Mechri A et al. Hyperhomocysteinemia and schizophrenia: case control study. Hyperhomocysteinemia and schizophrenia: case control study. Encephale 2011; 37 (4): 308–13. 19. Kim TH, Moon SW. Serum homocysteine and folate levels in Korean schizophrenic patients. Psychiat Invest 2011; 8 (2): 134–40. 20. Petronijević ND, Radonjić NV, Ivković MD et al. Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog Neuropsychopharmacol Biol Psychiat 2008; 32 (8): 1921–6. 21. Sazci A, Ergul E, Kucukali I et al. Association of the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene with schizophrenia: association is significant in men but not in women. Prog Neuropsychopharmacol Biol Psychiat 2005; 29 (7): 1113–23. 22. Levine J, Sela BA, Osher Y, Belmaker RH. High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiat 2005; 29 (7): 1181–91. 23. Applebaum J, Shimon H, Sela BA et al. Homocysteine levels in newly admitted schizophrenic patients. J Psychiat Res 2004; 38 (4): 413–6. 24. Haidemenos A, Kontis D, Gazi A et al. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiat 2007; 31 (6): 1289–96. 25. Jönsson EG, Larsson K, Vares M et al. Two methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms, schizophrenia and bipolar disorder: an association study. Am J Med Gen B Neuropsychiat Gen 2008; 147 (6): 976–82. 26. Yoshimi A, Aleksic B, Kawamura Y et al. Gene-wide association study between the methylenetetrahydrofolate reductase gene (MTHFR) and schizophrenia in the Japanese population, with an updated meta-analysis on currently available data. Schizophr Res 2010. 27. Roffman JL, Weiss AP, Purcell S et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiat 2008; 63 (1): 42–8. 28. Roffman JL, Brohawn DG, Friedman JS et al. MTHFR 677C>T effects on anterior cingulate structure and function during response monitoring in schizophrenia: a preliminary study. Brain Imag Behav 2011; 5 (1): 65–75. 29. Roffman JL, Weiss AP, Deckersbach T et al. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophr Res 2007; 92 (1–3): 181–8. 30. Joober R, Benkelfat C, Lal S et al. Association between the methylenetetrahydrofolate reductase 677C>T missense mutation and schizophrenia. Mol Psychiat 2000; 5 (3): 323–6. 31. Stoney CM, Engebretson TO. Plasma homocysteine concentrations are positively associated with hostility and anger. Life Sci 2000; 66 (23): 2267–75. 32. Tucker KL, Qiao N, Scott T et al. High homocysteine and low B vitamins predict cognitive decline in aging men: the veterans affairs normative aging study. Am J Clin Nutr 2005; 82 (3): 627–35. 33. Thompson GA, Kilpatrick IC. The neurotransmitter candidature of sulphur-containing excitatory amino acids in the mammalian central nervous system. Pharmacol Ther 1996; 72: 25–36. 34. Lipton SA, Kim WK, Choi YB et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proc Natl Acad Sci USA 1997; 94 (11): 5923–8. 35. Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications 2008; p. 287–98. 36. Shi Q, Savage JE, Hufeisen SJ et al. l-Homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists. J Pharmacol Exp Ther 2003; 305: 131–42. 37. Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 2002; 70 (5): 694–702. 38. Ho PI, Ashline D, Dhitavat S et al. Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol Dis 2003; 14 (1): 32–42. 39. Kruman II, Culmsee C, Sic L et al. Mattson homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neuroscience 2000; 20 (18): 6920–6. 40. Linnebank M, Lutz H, Jarre E et al. Binding of copper is a mechanism of homocysteine toxicity leading to COX deficiency and apoptosis in primary neurons, PC12 and SHSY-5Y cells. Neurobiol Dis 2006; 23 (3): 725–30. 41. Kim WK, Pae YS. Involvement of N-methyl-d-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture. Neurosci Lett 1996; 216 (2): 117–20. 42. Imamura K, Takeshima T, Nakaso K, Nakashima K. Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture. Neuroreport 2007; 18 (13): 1319–22. 43. Borowczyk K, Shih DM, Jakubowski H. Metabolism and neurotoxicity of homocysteine thiolactone in mice: evidence for a protective role of paraoxonase. J Alzheimers Dis 2012; 30 (2): 225–31. 44. Görtz P, Hoinkes A, Fleischer W et al. Implications for hyperhomocysteinemia: not homocysteine but its oxidized forms strongly inhibit neuronal network activity. J Neurol Sci 2004; 218 (1–2): 109–14. 45. Арзуманян Е.С., Степанова М.С. Механизмы токсического действия гомоцистеиновой кислоты на нейрональные клетки. Нейрохимия. 2010; 27 (3): 251–6. 46. Boldyrev AA. Molecular mechanisms of homocysteine toxicity. Biochemist (Mosc) 2009; 74 (6): 589–98. 47. Alexopoulos P, Lehrl S, Richter-Schmidinger T et al. Short-term influence of elevation of plasma homocysteine levels on cognitive function in young healthy adults. J Nutr Health Aging 2010; 14 (4): 283–7. 48. Roffman JL, Nitenson AZ, Agam Y et al. Hypomethylating variant of MTHFR, 677C>T, blunts the neural response to errors in patients with schizophrenia and healthy individuals. PLoS One 2011; 6 (9): e25 253. 49. Goff DC, Bottiglieri T, Arning E et al. Homocysteine and negative symptoms in schizophrenia. Am J Psychiat 2004; 161: 1705–8. 50. Spiro HR, Schimke RN, Welch JP. Schizophrenia in a patient with a defect in methionine metabolism. J Nerv Ment Dis 1965; 141: 285–90. 51. Cohen SM, Nichols A, Wyatt R, Pollin W. The administration of methionine to schizophrenic patients: a review of ten studies. Biol Psychiat 1974; 8: 209–25. 52. Brune GG, Himwich HE. Effects of methionine loading on behavior of schizophrenic patients. J Nerv Ment Dis 1962; 134: 447–50. 53. Roffman JL, Weiss AP, Deckersbach T et al. Interactive effects of COMT Val108/158 Met and MTHFR C677T on executive function in schizophrenia. Am J Med Gen B Neuropsychiat Gen 2008; 147 (6): 990–5. 54. Roffman JL, Gollub RL, Calhoun VD et al. MTHFR 677C>T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val>Met Proc Natl Acad Sci USA 2008; 105 (45): 17 573–8. 55. Mudd SH, Freeman JM. N-5,10-methylenetetrahydrofolate reductase deficiency and schizophrenia: a working hypothesis. J Psychiat Res 1974; 11: 259–62. 56. Godfrey PS, Toone BK, Carney MW et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990; 336: 392–5. 57. Hill M, Shannahan K, Jasinski S et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res 2011. 58. Levine J, Stahl Z, Sela BA et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiat 2006; 60 (3): 265–9. 59. Zammit S, Lewis S, Gunnell D, Smith GD. Schizophrenia and neural tube defects: comparisons from an epidemiological perspective. Schizophr Bull 2007; 33 (4): 853–8.